No Picture
News

Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.
“Mirati is working to d… […]

No Picture
News

Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine

Technology, expertise from UK’s Mucokinetica to accelerate repurposing of generic remedy nafamostat for COVID-19 oral, inhalation therapy

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — A biopharmaceutical company repurposing nafamostat, a generic remedy for… […]

No Picture
News

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended  June 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]

No Picture
News

Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARLSBAD, Calif., Aug. 4, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, wit… […]

No Picture
News

HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology

 SAN DIEGO, Aug. 4, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIO

®
), the leader in accelerating global development of China’s pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, … […]